<DOC>
	<DOCNO>NCT01256697</DOCNO>
	<brief_summary>Retinitis pigmentosa genetically determine disease consist progressive centripetal retinal degeneration start rod out segment . Its prevalence 1:4000 people fourth common blind disease Israel 2004 [ 7 % blindness ] . The investigator try treat non-progressive form disease [ Fundus Albipunctatus ] oral therapy food supplement make alga Dunaliella bardawil compose approximately 50 % 9-cis β-carotene . The alga Dunaliella bardawil accumulate high concentration β -carotene grown appropriate condition . The β -carotene alga compose approximately 50 % all-trans - β carotene 50 % 9-cis β -carotene . The 9-cis β -carotene show precursor 9-cis retinoic acid in-vitro human intestinal mucosa in-vivo ferret , perfuse 9-cis b-carotene . The night vision , measure objectively electroretinography ( ERG ) double six patient test . The visual field also improve significantly .</brief_summary>
	<brief_title>The Effect Oral Administration 9-cis Rich Powder Alga Dunaliella Bardawil Visual Functions im Patients With Retinitis Pigmentosa</brief_title>
	<detailed_description />
	<mesh_term>Retinitis</mesh_term>
	<mesh_term>Retinitis Pigmentosa</mesh_term>
	<criteria>Written inform consent participate study . Men woman age 18 year old . Electroretinogram ( ERG ) responses compatible diagnosis Retinitis Pigmentosa Current smoker . Current use Vitamin A/ beta carotene supplement . Active arterial disease within 3 month study entry unstable angina , myocardial infarction , transient ischemic attack ( TIA ) , stroke , coronary artery bypass graft ( CABG ) surgery . History malignancy , except basal squamous cell skin carcinoma . Pregnant woman , woman breast feeding , woman childbearing potential use chemical mechanical contraception . Uncontrolled hypertension define either rest diastolic blood pressure &gt; 95mmHg ( take mean 3 reading ) rest systolic blood Pressure &gt; 180 mmHg . History alcohol abuse drug abuse , . Patient plan engage vigorous exercise aggressive diet regimen . Uncontrolled endocrine metabolic disease . Participation another investigational drug study within 4 week entry study . Serious unstable medical psychological condition , opinion investigator , would compromise subject 's safety successful participation study . Subject whose hormone replacement therapy ( HRT ) oral contraceptive therapy ( OCT ) initiate within 3 month prior enrollment .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2013</verification_date>
</DOC>